Sunesis Pharmaceuticals Inc.
This article was originally published in Start Up
The drawbacks associated with protein drugs--including the injectable mode of delivery and the high costs of goods--have led a number of biotech and pharmaceutical companies to use their protein engineering capabilities for small molecule drug discovery. Fledging Sunesis Pharmaceuticals Inc. has leapt into the fray with what its management believes is a unique combination of robust proprietary technology and integrated capabilities in medicinal chemistry and protein engineering.
You may also be interested in...
Nuevolution is a Danish biotechnology company that aims to generate an ultra-large library of small molecules more than a million times larger than the largest existing industry libraries. By applying its Chemetics evolution-mimicing screening approach Nuevolution hopes to very rapidly select the best ligands to any drug target.
Kinetix Pharmaceuticals hoped that a focus on a particular class of targets that shares structural similarities--the protein kinases--would yield small molecules for a variety of therapeutic areas. But in order to realize synergies between multiple research projects in protein kinases, the company couldn't partner the projects out to numerous pharmaceutical partners, each requiring exclusivity and confidentiality. After technological rival Vertex signed a multi-million dollar protein kinase development partnership with Novartis, Kinetix began to rethink its original business model. A $170 million acquisition offer by Amgen Inc. made strategic sense for the start-up.
Formed by Kalamazoo-based Pharmacia alumni, AureoGen Biosciences Inc. is genetically engineering cyclic peptides to create second-generation, resistance-proof anti-infective and anti-fungal therapeutics.